Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

<p>Gene expression of major signalling pathways and multiplex immunohistochemical comparison of markers between timepoints and tumor sites. A) Gene expression of related oncogenic signalling pathways between treatment timepoints and site, B) Estimated mean difference of proteins and pathways b...

Бүрэн тодорхойлолт

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	James S. Wilmott (15008931) (author)
Бусад зохиолчид:	Hussein Tawbi (15054769) (author), Johnathan A. Engh (15054772) (author), Nduka M. Amankulor (15054775) (author), Brindha Shivalingam (15054778) (author), Hiya Banerjee (15054781) (author), Ismael A. Vergara (15054784) (author), Hansol Lee (15054787) (author), Peter A. Johansson (15054790) (author), Peter M. Ferguson (15054793) (author), Philippe Saiag (15054796) (author), Caroline Robert (15032672) (author), Jean-Jacques Grob (15054799) (author), Lisa H. Butterfield (15035537) (author), Richard A. Scolyer (10778711) (author), John M. Kirkwood (15023483) (author), Georgina V. Long (11420813) (author), Michael A. Davies (14932995) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Tumor Biology Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase II clinical trials Skin Cancers Melanoma Small Molecule Agents Kinase inhibitors Tumor Microenvironment Immune cells and the microenvironment
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
-н: James S. Wilmott (15008931)
Хэвлэсэн: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
-н: Qingsheng Xu (17078830)
Хэвлэсэн: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
-н: Qingsheng Xu (17078830)
Хэвлэсэн: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
-н: Tom Wei-Wu Chen (15053003)
Хэвлэсэн: (2025)

Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
-н: Andrés Elía (15055031)
Хэвлэсэн: (2025)

Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
-н: Andrés Elía (15055031)
Хэвлэсэн: (2025)

Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
-н: Andrés Elía (15055031)
Хэвлэсэн: (2025)

Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
-н: Andrés Elía (15055031)
Хэвлэсэн: (2025)

Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
-н: Andrés Elía (15055031)
Хэвлэсэн: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
-н: Alexander N. Shoushtari (15023909)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
-н: Zachary Quinn (15052893)
Хэвлэсэн: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
-н: John A. Ligon (15024477)
Хэвлэсэн: (2025)

Supplementary Tables S1-S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
-н: Axel Stenmark Tullberg (15029928)
Хэвлэсэн: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
-н: Giuseppe Basile (15051269)
Хэвлэсэн: (2025)

Supplementary Data Tables 1 from Immunogenomic Landscape of Neuroendocrine Prostate Cancer
-н: Bhavneet Bhinder (14963342)
Хэвлэсэн: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
-н: Roger Li (17078665)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
-н: Ulka N. Vaishampayan (15051039)
Хэвлэсэн: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
-н: Nam Q. Bui (14958210)
Хэвлэсэн: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
-н: Nigel Bundred (15046233)
Хэвлэсэн: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
-н: Fabrice Barlesi (15045504)
Хэвлэсэн: (2025)

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
-н: Fabrice Barlesi (15045504)
Хэвлэсэн: (2025)

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
-н: Fabrice Barlesi (15045504)
Хэвлэсэн: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
-н: Fabrice Barlesi (15045504)
Хэвлэсэн: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
-н: Fabrice Barlesi (15045504)
Хэвлэсэн: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
-н: Dwight H. Owen (15034782)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_hnbm91b50q3n0m2bl0p2jfhmnv